HENGRUI USA
  • HOME
  • ABOUT
    • About Hengrui
    • Meet Our Team
    • Our Location
  • R&D
  • CAREERS
  • NEWS
  • CONTACT US
  • HOME
  • ABOUT
    • About Hengrui
    • Meet Our Team
    • Our Location
  • R&D
  • CAREERS
  • NEWS
  • CONTACT US

HENGRUI NEWS


​May 2022  PRESS RELEASE

Jiangsu Hengrui Pharmaceuticals Co., Ltd. launches Luzsana Biotechnology™

Feb 22, 2022
​

HengRui USA Wins 2022 Top Workplaces Regional Award

April 27, 2021
​

HengRui USA Announces FDA Grants Orphan Drug Designation of Camrelizumab for "Treatment of Hepatocellular Carcinoma"

Feb 24, 2021
​

HengRui USA Announces the Launch of In-House Clinical Operations in US with 1st Subject Screened in Study Evaluating SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subject

Feb 05, 2021
​

HengRui USA Announces First US Patient Screened in Study Evaluating INS068 in Patients with Type 2 Diabetes Mellitus

Nov 28, 2020
​

HengRui USA Announces Successful Completion of Dosing in Cohort 1 in the Single Ascending Dose Trial with HRS4800

About

About HengRui
Meet Our Team
Locations

R&d



CONTACT US

​CAREERS

HENGRUI USA © COPYRIGHT 2020. ALL RIGHTS RESERVED.